Nuvectis Pharma annual meeting elects director; proxy share count corrected

Nuvectis Pharma, Inc.

Proxy mistakenly stated 27,668,036 shares outstanding; correct count is 26,614,628.
Quorum of 60.8% (16,193,686 shares) present at June 11, 2026 annual meeting.
Ron Bentsur elected Class I director with 8,354,838 votes for, 391,265 against.
Kesselman & Kesselman ratified as independent auditor for FY2026 (15,662,222 for).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Nuvectis Pharma, Inc. shareholders approved Election of Class I director to hold office until the 2029 annual meeting at the 2026-06-11 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

The vote with respect to the election of the Class I director to hold office until the 2029 annual meeting was as follows: Director Votes For Votes Against Abstentions / Votes Withheld Broker Non-Votes Ron Bentsur 8,354,838 391,265 216 7,447,367

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Nuvectis Pharma, Inc. shareholders approved Ratification of Kesselman & Kesselman as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

The vote with respect to the ratification of Kesselman & Kesselman as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was as follows: Votes For Votes Against Abstentions / Votes Withheld Broker Non-Votes 15,662,222 10,574 520,890 -

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Nuvectis Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-073419

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.